Literature DB >> 8183574

Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.

R Rottapel1, C W Turck, N Casteran, X Liu, D Birnbaum, T Pawson, P Dubreuil.   

Abstract

Flt3 is a receptor tyrosine kinase (RTK) structurally related to the CSF-1R encoded by the c-fms locus, Kit and the PDGFR which is restricted in its expression to hematopoietic precursor populations and several distinct cell types within the central nervous system. Although the ligand for Flt3 has recently been identified, the developmental function of Flt3 within these tissues has not yet been described. In order to examine the signalling properties of this receptor, we previously constructed a chimeric molecule containing the extracellular domain of CSF-1R fused to the transmembrane and cytoplasmic domain of mouse Flt3 (FF3). The ability of the FF3 to directly associate with or tyrosine phosphorylate specific cytoplasmic signalling molecules in vivo was examined. GAP, Vav, Shc, and to a lesser extent PLC gamma become tyrosine-phosphorylated but no in vivo association with the receptor was detectable. FF3 associates with PI3K activity and the SH2 domains of p85 and Grb-2. Phosphopeptide competition experiments suggest that the PI3K binding site is located outside of the kinase insert in the carboxy tail of the receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183574

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 2.  Signal transduction of oncogenic Flt3.

Authors:  Chunaram Choudhary; Carsten Müller-Tidow; Wolfgang E Berdel; Hubert Serve
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  IL-6 blocks a discrete early step in lymphopoiesis.

Authors:  Kazuhiko Maeda; Yoshihiro Baba; Yoshinori Nagai; Kozo Miyazaki; Alexander Malykhin; Koji Nakamura; Paul W Kincade; Nobuo Sakaguchi; K Mark Coggeshall
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

4.  Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation.

Authors:  P De Sepulveda; K Okkenhaug; J L Rose; R G Hawley; P Dubreuil; R Rottapel
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

5.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Authors:  Li Li; Obdulio Piloto; Ho Bao Nguyen; Kathleen Greenberg; Kogo Takamiya; Frederick Racke; David Huso; Donald Small
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

Review 6.  Structural and functional alterations of FLT3 in acute myeloid leukemia.

Authors:  Soheil Meshinchi; Frederick R Appelbaum
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

7.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard Stone; Ilene Galinsky; Edward Fox; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

8.  Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status.

Authors:  Alessandra Cesano; Santosh Putta; David B Rosen; Aileen C Cohen; Urte Gayko; Kavita Mathi; John Woronicz; Rachael E Hawtin; Larry Cripe; Zhuoxin Sun; Martin S Tallman; Elisabeth Paietta
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

9.  Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.

Authors:  S Zhang; S Fukuda; Y Lee; G Hangoc; S Cooper; R Spolski; W J Leonard; H E Broxmeyer
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

10.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.